Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTENT: Immunogenicity in Patients Failing Response on Anti-TNF
2015-002284-42Phase 4Completed
- Sponsor
- READE
- Start
- Aug 2015
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of etanercept, adalimumab, certolizumab pegol, golimumab and infliximab in rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and 1 more (5 arms), sponsored by READE. Primary endpoint: Primary endpoint Phase 1. Started Aug 2015; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)psoriatic arthritis (PsA)ankylosing spondylitis (AS)psoriasis
Beyond the preview
Go deeper on 2015-002284-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002284-42.